On Day 3, the Sagility IPO subscription status is Oversubscribed by 2.2 times, driven mainly by high retail and employee interest. While retail investors subscribed 2.24 times, institutional interest was lower. The IPO, priced at ₹28-30, aims to raise ₹2,106.6 crore.
Sagility India IPO GMP Today
As of today, Sagility India’s IPO is trading at a modest ₹3 premium in the grey market. This relatively low GMP may indicate caution among investors, as it suggests the demand might not be exceptionally strong at this stage. Grey market premiums are a reflection of market sentiment, and in this case, the muted GMP signals a cautious outlook.
Sagility India IPO Subscription Status– Day 3
The Sagility IPO as of now so far, its Day 3 with an overall subscription rate of 2.2 times, largely thanks to strong interest from retail investors and company employees. The retail investor segment was especially enthusiastic, subscribing about 2.24 times, while employees showed solid support with a 2.44x subscription. However, demand was more cautious among institutional investors, with the non-institutional investor (NII) category reaching only 24%, and qualified institutional buyers (QIBs) subscribing around 7% by the close of Day 2, though a slight rise was expected as final bids came in.
Sagility India IPO Good or Bad Investment?
Investors are weighing several factors for the Sagility IPO review. On one hand, the healthcare sector is generally seen as resilient with long-term growth potential. On the other hand, the IPO’s OFS structure, which does not contribute to Sagility’s expansion, may limit appeal. The low GMP and slower initial subscription rates also suggest that investors are cautious. For those looking to invest, the IPO might be more attractive if QIB participation increases, signaling broader institutional confidence.
Sagility India IPO Listing Price Forecast
Based on the current GMP and subscription levels, Sagility India’s IPO listing price may remain close to or slightly above the issue price. A significant boost in subscriptions, especially from QIBs, could increase listing-day performance. However, if subscription demand stays low, the listing might not offer substantial immediate gains. As of today GMP showing 3 rupees, as per GMP expected Listing price is 33 ruppes. Please note gmp might change till listings.
Should You Buy Sagility India IPO or Not?
For those evaluating whether Sagility India IPO is a good buy, it depends on risk tolerance and investment goals:
- For Cautious Investors: The slow Day 1 response and low GMP suggest a more measured approach might be wise, especially if the subscription rate doesn’t increase substantially by closing day.
- For Long-Term Investors: Sagility’s focus in the healthcare sector could be a positive for those with a long-term outlook, though the absence of fresh capital from this IPO could impact near-term growth initiatives.
Sagility IPO Subscription and Stratergy for Investors
- If Subscription Remains Low (Undersubscription): Caution may be advisable, as undersubscribed IPOs sometimes see lower demand on listing day.
- If Subscription Increases (Oversubscription): A stronger QIB participation could be a positive sign, and those considering an investment might gain more confidence. Watching for any increases in GMP could also provide further guidance.
In conclusion, Sagility India’s IPO presents both opportunities and risks. Those interested should keep an eye on subscription trends and grey market premium fluctuations as the closing day approaches.
Financial Disclaimer
The information in this article regarding the Sagility India IPO is for informational purposes only and should not be taken as financial advice. Investing in IPOs carries risks, including loss of principal. Always conduct your own research or consult a financial advisor before making investment decisions. The author assumes no responsibility for any losses incurred from reliance on this information.
TOP FAQ
What’s the current grey market premium (GMP) for Sagility India IPO?
The GMP is ₹3, indicating cautious demand among investors.
Is it a good investment?
It depends on your risk tolerance. The healthcare sector is stable, but this IPO doesn’t fund company growth directly.
What’s the listing price forecast?
The listing price is expected to be around 33 Rupees, unless institutional interest picks up significantly.
What are the Day 1 subscription figures?
The IPO is 0.13 times subscribed so far, mainly driven by retail investors.
Should I buy now or wait?
If demand stays low, it might be wise to wait, as undersubscribed IPOs can perform poorly at listing. Increased institutional interest could change this.